pimobendan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
cardiac stimulants, pimobendan derivatives	2171	74150-27-9

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

UD-CG 115 BS
UDCG 115
pimobendan
acardi

produces arterial & venous dilatation in dogs; structure given in first source

Molecular weight: 334.38
Formula: C19H18N4O2
CLOGP: 2.90
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 79.37
ALOGS: -4.36
ROTB: 3

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	2 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	14 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1994	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	92.98	49.38	28	237	76012	50528847

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	61.44	41.74	27	382	79260	29494858

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cardiac failure	132.07	41.06	52	731	132321	64365628
Renal impairment	45.11	41.06	25	758	134992	64362957

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D010726	Phosphodiesterase Inhibitors
MeSH PA	D020011	Protective Agents
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:38147	cardiotonic drugs
CHEBI has role	CHEBI:50218	phosphodiesterase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Congestive heart failure caused by atrioventricular valvular insufficiency or dilated cardiomyopathy	Indication
Dogs	Use with concurrent therapy for congestive heart failure	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Vetmedin	Boehringer lngelheim Animal Health USA Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.86	acidic
pKa2	11.61	acidic
pKa3	4.76	Basic
pKa4	4.16	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Phosphodiesterase 3	Enzyme	Q13370 Q14432	PDE3B_HUMAN PDE3A_HUMAN	INHIBITOR	IC50	6.39		CHEMBL	SCIENTIFIC LITERATURE
Type-1 angiotensin II receptor	GPCR		AGTR1_BOVIN		IC50	4.77		CHEMBL

External reference:

ID	Source
D01133	KEGG_DRUG
C0071071	UMLSCUI
CHEBI:32003	CHEBI
CHEMBL24646	ChEMBL_ID
DB11450	DRUGBANK_ID
C041648	MESH_SUPPLEMENTAL_RECORD_UI
4823	PUBCHEM_CID
5090	INN_ID
34AP3BBP9T	UNII
1110783	RXNORM
017800	NDDF

Pharmaceutical products:

None